• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性牙周炎对 0 期药物相关性颌骨坏死发展的影响。

The effect of chronic dental inflammation on development of Stage 0 medication-related osteonecrosis of the jaw.

机构信息

Department of Oral and Maxillofacial Surgery, (Head: Prof. Osman Taha Koseoglu), Faculty of Dentistry, Hacettepe University, Ankara, Turkey.

Department of Oral and Maxillofacial Surgery, (Head: Prof. Osman Taha Koseoglu), Faculty of Dentistry, Hacettepe University, Ankara, Turkey.

出版信息

J Craniomaxillofac Surg. 2017 Aug;45(8):1158-1164. doi: 10.1016/j.jcms.2017.05.003. Epub 2017 May 12.

DOI:10.1016/j.jcms.2017.05.003
PMID:28601298
Abstract

OBJECTIVE

The pathogenesis of medication-related osteonecrosis of jaw (MRONJ) is poorly understood. The aim of this prospective study was to determine the effect of chronic dental inflammation on the development of Stage 0 MRONJ based on histopathological findings.

METHODS

The study involved patients with a history of bisphosphonate use and an indication for tooth extraction. Before surgery, C-terminal telopeptide test (CTX) values were collected from all patients. All tooth extractions were performed according to a determined protocol. To detect whether any medication-related osteonecrotic changes were present in the non-exposed bone, biopsy samples were taken from the alveolar bone.

RESULTS

A total of 50 patients were included in the study (39 women and 11 men). The patients were mean age of 57.4 ± 12.1 years. In total, 74 teeth were extracted (29 maxillary and 45 mandibular). Histologic examination of three patients (6%) revealed Stage 0 MRONJ. Postoperatively, the complete mucosal healing success rate was 96%. MRONJ risk was not significantly correlated with low CTX value (p = 0.285).

CONCLUSIONS

Chronic inflammation may contribute to Stage 0 MRONJ; however, its role may not be sufficient alone for its development. Application of a predetermined protocol for dentoalveolar processes will help to prevent MRONJ development.

摘要

目的

药物相关性颌骨坏死(MRONJ)的发病机制尚不清楚。本前瞻性研究旨在根据组织病理学发现,确定慢性牙周炎对 0 期 MRONJ 发展的影响。

方法

该研究纳入了有双膦酸盐使用史且需要拔牙的患者。所有患者均采集 C 末端肽(CTX)值。所有拔牙均按照既定方案进行。为了检测非暴露骨中是否存在任何与药物相关的骨坏死变化,从牙槽骨中采集活检样本。

结果

共有 50 例患者(39 名女性和 11 名男性)纳入研究。患者的平均年龄为 57.4±12.1 岁。共拔除 74 颗牙齿(29 颗上颌和 45 颗下颌)。3 名患者(6%)的组织学检查显示为 0 期 MRONJ。术后,完全黏膜愈合成功率为 96%。MRONJ 风险与低 CTX 值无显著相关性(p=0.285)。

结论

慢性炎症可能导致 0 期 MRONJ;但仅慢性炎症可能不足以导致其发生。应用预先确定的牙槽骨处理方案有助于预防 MRONJ 的发生。

相似文献

1
The effect of chronic dental inflammation on development of Stage 0 medication-related osteonecrosis of the jaw.慢性牙周炎对 0 期药物相关性颌骨坏死发展的影响。
J Craniomaxillofac Surg. 2017 Aug;45(8):1158-1164. doi: 10.1016/j.jcms.2017.05.003. Epub 2017 May 12.
2
Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor?影响接受大剂量双膦酸盐或地舒单抗治疗的癌症患者药物相关性颌骨坏死发展的因素:拔牙是否为危险因素?
PLoS One. 2018 Jul 26;13(7):e0201343. doi: 10.1371/journal.pone.0201343. eCollection 2018.
3
Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.药物相关性颌骨坏死:双膦酸盐治疗患者与抗吸收-抗血管生成药物治疗患者的风险因素
Minerva Stomatol. 2017 Aug;66(4):135-140. doi: 10.23736/S0026-4970.17.04056-0. Epub 2017 May 10.
4
Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab.拔牙后进行一期伤口缝合以预防接受地诺单抗治疗患者的药物相关性颌骨坏死
Clin Oral Investig. 2017 Jan;21(1):127-134. doi: 10.1007/s00784-016-1762-y. Epub 2016 Feb 29.
5
Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study.癌症患者拔牙后与药物相关的颌骨坏死:一项多中心回顾性研究。
Osteoporos Int. 2019 Jan;30(1):231-239. doi: 10.1007/s00198-018-4746-8. Epub 2018 Nov 7.
6
Influence of induced infection in medication-related osteonecrosis of the jaw development after tooth extraction: A study in rats.拔牙后药物相关性颌骨坏死发展过程中诱导感染的影响:一项大鼠研究。
J Craniomaxillofac Surg. 2019 Feb;47(2):349-356. doi: 10.1016/j.jcms.2018.08.011. Epub 2018 Aug 28.
7
Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development?接受口服或静脉注射双膦酸盐治疗的患者拔牙:引发药物性颌骨坏死的诱因?
J Craniomaxillofac Surg. 2015 Jul;43(6):847-54. doi: 10.1016/j.jcms.2015.03.039. Epub 2015 Apr 10.
8
Does inflammatory dental disease affect the development of medication-related osteonecrosis of the jaw in patients using high-dose bone-modifying agents?炎症性牙科疾病是否会影响使用大剂量骨改良药物的患者发生药物相关性颌骨坏死的发展?
Clin Oral Investig. 2021 May;25(5):3087-3093. doi: 10.1007/s00784-020-03632-7. Epub 2020 Oct 14.
9
What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review.抗吸收药物 (ARDs) 对骨质疏松症患者药物相关性颌骨坏死 (MRONJ) 发展的影响:系统评价。
J Craniomaxillofac Surg. 2017 Sep;45(9):1493-1502. doi: 10.1016/j.jcms.2017.05.028. Epub 2017 Jun 3.
10
A retrospective study of osteomyelitis and osteonecrosis of the jaws and its etiologic implication of bisphosphonate in Asians.亚洲地区双膦酸盐相关性颌骨骨髓炎和骨坏死的回顾性研究及其病因学意义。
Clin Oral Investig. 2017 Jun;21(5):1905-1911. doi: 10.1007/s00784-016-1973-2. Epub 2016 Oct 22.

引用本文的文献

1
Clinical Performance of Implant-Supported Prostheses in the Rehabilitation of Patients Previously Treated for Medication-Related Osteonecrosis of the Jaws (MRONJ): A Systematic Review.种植体支持式修复体用于曾接受药物相关性颌骨坏死(MRONJ)治疗患者康复的临床性能:一项系统评价
Cureus. 2024 Jun 4;16(6):e61658. doi: 10.7759/cureus.61658. eCollection 2024 Jun.
2
Nonexposed antiresorptive agent-related osteomyelitis of the jaw: a single-center cohort study.非暴露性抗吸收剂相关性颌骨骨髓炎:一项单中心队列研究。
J Bone Miner Metab. 2022 Jul;40(4):657-662. doi: 10.1007/s00774-022-01329-3. Epub 2022 May 9.
3
The preventive care of medication-related osteonecrosis of the jaw (MRONJ): a position paper by Italian experts for dental hygienists.
预防药物相关性颌骨坏死(MRONJ):意大利专家为口腔卫生师制定的立场文件。
Support Care Cancer. 2022 Aug;30(8):6429-6440. doi: 10.1007/s00520-022-06940-8. Epub 2022 Mar 16.
4
[Management of medication-related osteonecrosis of the jaw-a review of recent study results in comparison to established strategies].[药物相关性颌骨坏死的管理——与既定策略相比的近期研究结果综述]
HNO. 2022 Jul;70(7):499-507. doi: 10.1007/s00106-021-01130-0. Epub 2022 Jan 20.
5
Rescue bisphosphonate treatment of alveolar bone improves extraction socket healing and reduces osteonecrosis in zoledronate-treated mice.唑来膦酸治疗小鼠牙槽骨骨坏死中,挽救性双膦酸盐治疗可改善拔牙窝愈合。
Bone. 2019 Jun;123:115-128. doi: 10.1016/j.bone.2019.03.027. Epub 2019 Mar 26.
6
Biomarkers to predict the onset of biphosphonate-related osteonecrosis of the jaw: A systematic review.预测双膦酸盐相关颌骨坏死发病的生物标志物:一项系统评价
Med Oral Patol Oral Cir Bucal. 2019 Jan 1;24(1):e26-e36. doi: 10.4317/medoral.22763.